$CE · Celanese Corp
Celanese Corporation reported Q3 2026 results with adjusted EPS of $1.65, exceeding its own guidance, on net sales of $2.556B (up 6% YoY). The company raised full-year 2026 adjusted EPS guidance to $6.00–$6.25 and lifted its free cash flow outlook to $750–$800M. Q3 operating cash flow was $538M and free cash flow was $461M, supporting accelerated deleveraging toward a targeted ~4.7x net debt-to-EBITDA by year-end.
- Q3 adjusted EPS of $1.65 exceeded company guidance; GAAP EPS was $0.68.
- Net sales of $2.556B rose 6% YoY, driven by strategic growth initiatives and commercial actions.
- Operating cash flow hit $538M and free cash flow reached $461M in Q3 alone.
- Full-year 2026 adjusted EPS guidance raised to $6.00–$6.25; free cash flow outlook lifted to $750–$800M.
- Company expects net debt-to-operating EBITDA of ~4.7x by year-end 2026, reflecting deleveraging progress.
Extended-hours trading shows CE at $49.50, up +3.36% vs the regular-session close of $47.89, indicating a positive initial reaction to the beat-and-raise quarter.
A beat-and-raise quarter with sharply higher free cash flow guidance signals accelerating deleveraging and improving earnings quality at a time when chemical-sector peers face demand headwinds.
Celanese's beat-and-raise contrasts with mixed chemical-sector results; strong acetyl chain pricing and medical/electronics mix enrichment in Engineered Materials signal differentiated execution in a still-dynamic macro environment.
Forward-looking risks include raw material and energy price volatility (ethylene, methanol, natural gas), automotive and construction cycle exposure, and execution risk on the $1B divestiture target by end of 2027.